Cover Image
市場調查報告書

改變T細胞受體 (TCR) 、嵌合抗原受體 (CAR) 免疫療法:2015年

Engineered TCR and CAR Immunotherapeutics 2015

出版商 La Merie Publishing 商品編碼 325905
出版日期 內容資訊 英文 201 Pages
訂單完成後即時交付
價格
Back to Top
改變T細胞受體 (TCR) 、嵌合抗原受體 (CAR) 免疫療法:2015年 Engineered TCR and CAR Immunotherapeutics 2015
出版日期: 2015年03月13日 內容資訊: 英文 201 Pages
簡介

本報告提供改變T細胞受體 (TCR) 、嵌合抗原受體 (CAR) 免疫療法調查分析、簡介、開發平台分析、主要企業、主要技術簡介、TCR、CAR免疫療法預測等相關的系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 TCR、CAR免疫療法、NK細胞、TIL、DLI、CTL簡介

  • TCR融合蛋白品質、抗體
  • 自體TCR T細胞 (固態腫瘤、骨髓惡性腫瘤)
  • CD19 CAR T細胞
  • 其他自體CAR T細胞 (骨髓惡性腫瘤)
  • 自體CAR T細胞 (固態腫瘤)
  • 同類CAR T細胞
  • 萬能CAR T細胞
  • NK細胞、TIL、DLI、CTL

第4章 開發平台分析

  • TCR 抗體、融合蛋白質、TCR狀 抗體
  • TCR T細胞
  • CD19 CAR T細胞
  • 其他CAR T細胞 (骨髓惡性腫瘤)
  • 其他CAR T細胞 (固態腫瘤)
  • 同類TCR、CAR T細胞
  • 萬能、抗體標的CAR T細胞
  • NK細胞、TIL、DLI、CTL

第5章 技術企業

  • Adaptimmune
  • Altor Bioscience
  • Applied Immune Technologies (AIT)
  • Atara Biotherapeutics
  • Autolus
  • Bellicum Pharmaceuticals
  • Bluebird bio
  • Cardio3 BioSciences
  • Cellectis
  • Cellular Biomedicine Group (CBMG)
  • Conkwest
  • CRISPR Therapeutics
  • CytomX
  • Editas Medicine
  • Eureka Therapeutics
  • Immunocore
  • Intellia Therapeutics
  • Intrexon, ZIOPHARM Oncology & MD Anderson
  • Juno Therapeutics
  • Kite Pharma
  • Lion Biotechnologies
  • MD Anderson Cancer Center
  • Medigene
  • Nextera
  • Sorrento Therapeutics
  • TaKaRa BIO
  • ransposagen Biopharmaceuticals
  • Unum Therapeutics

第6章 製藥企業

  • Amgen
  • AstraZeneca
  • Celgene
  • Eli Lilly
  • GlaxoSmithKline
  • Janssen Biotech
  • Novartis
  • Pfizer
  • Roche
  • Servier

第7章 相關利益者分析

第8章 主要技術簡介

第9章 TCR、CAR免疫療法的產業預測

第10章 TCR、CAR免疫療法預測

第11章 參考資料

圖表

目錄
Product Code: LMFR0015

The engineered T cell receptor (TCR) for targeting of intracellular targets not druggable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding partnering and financing deals concluded within the last two years.

Leveraging the power of T cells by cellular and recombinant immunotherapeutics

 Intra-cellular TargetsCAR T Cells
(autologous/allogeneic)
CellularTCR T CellsRevenue, units
RecombinantBispecific TCR-anti-CD3
(e.g. ImmTACs)
Bispecific antibodies
(incl. anti-CD3)

This report “Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs” as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies.

However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities.

This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

  • Profiles of TCR and CAR immunotherapeutics in development;
  • Competitor analysis of CD19 CAR T cells;
  • Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value;
  • Target analysis of TCR T cells in R&D;
  • CAR T Cell pipeline in hematology;
  • CAR T Cell pipeline in solid tumors;
  • Allogeneic TCR and CAR T cells in R&D;
  • Universal antibody-targeted CAR T cells and NK cells;
  • Pipeline of most promising TILs, NK cells, DLIs and CTLs;
  • Technologies needed for next generations of TCR and CAR immunotherapeutics;
  • Profiles of biotechnology companies incl. financing and licensing/partnering;
  • Profiles and scope of interest of Big Pharma/Biotech for TCRs & CARs;
  • Stakeholder analysis (established, emerging, non-US, technology providers);
  • Potential of alternative adoptive immunotherapies (NKs, TILs, CTLs, DLIs);
  • Analysis of major partnering deals (Big pharma & biotech);
  • Economic terms of pharma-biotech deals;
  • Opportunities for biotech-biotech deals in the TCR and CAR field;
  • Potential to raise private money with TCR and CAR technologies;
  • Success in initial public offerings and follow on offerings with TCRs and CARs;
  • Limitations and hurdles with current TCR and CAR immunotherapeutics;
  • Opportunities for novel TCR and CAR immunotherapeutics;
  • Pricing of TCR and CAR immunotherapeutics;
  • Aspects of manufacturing and commercialization.

Table of Contents

1. Introduction

2. Executive Summary

3. Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs

  • 3.1. TCR Fusion Proteins & Antibodies
    • ALT-801
    • IMCgp100
    • ESK1 / ESKM3.2
  • 3.2. Autologous TCR T Cells for Solid Tumors & Hematologic Malignancies
    • NY-ESOc259T
    • JCAR016
    • TBI-1201
    • TBI-1301
    • BPX-701
  • 3.3. CD19 CAR T Cells
    • CTL019
    • HuCART19 (HuCTL019)
    • JCAR015
    • JCAR017
    • JCAR014
    • KTE-C19
    • CD19-CAR T cells (Takara)
    • BPX-401
  • 3.4. Other Autologous CAR T Cells for Hematological Malignancies
    • CART123
    • CM-CS1
  • 3.5. Autologous CAR T Cells for Solid Tumors
    • G2-CAR.OX4028.z.ICD19
    • BPX-601
    • CAR-NKp30/B7H6
    • CART-EGFRvIII
    • CART-meso T cells
  • 3.6. Allogeneic CAR T Cells
    • UCART19
    • UCART38
    • UCART123
    • UCARTCS1
  • 3.7. Universal CAR T cells
    • ATTCK20
  • 3.8. NK Cells, TILs, DLIs & CTLs
    • Natural Killer (NK) cells: Neukoplast / NK-92
    • NK cells: CD16-Neukoplast
    • NK cells: NK-92.ErbB2/Her2
    • Tumor Infiltrating Lymphocytes (TILs): LN-144 (Contego)
    • Donor Lymphocyte Infusion (DLI): BPX-501
    • Cytotoxic T-Lymphocytes (CTLs): EBV-CTL

4. Pipeline Analysis

  • 4.1. TCR Antibodies, Fusion Proteins and TCR-like Antibodies
  • 4.2. TCR T-Cells
  • 4.3. CD19 CAR T Cells
  • 4.4. Other CAR T Cells for Hematological Malignancies
  • 4.5. Other CAR T Cells for Solid Tumors
  • 4.6. Allogeneic TCR & CAR T Cells
  • 4.7. Universal, antibody-targeted CAR T Cells
  • 4.8. Natural Killer cells (NK cells), Tumor Infiltrating Lymphocytes (TILs), Donor Lymphocyte Infusions (DLIs) and Cytotoxic T Lymphocytes (CTLs)

5. Technology Companies

  • 5.1. Adaptimmune
  • 5.2. Altor Bioscience
  • 5.3. Applied Immune Technologies (AIT)
  • 5.4. Atara Biotherapeutics
  • 5.5. Autolus
  • 5.6. Bellicum Pharmaceuticals
  • 5.7. Bluebird bio
  • 5.8. Cardio3 BioSciences
  • 5.9. Cellectis
  • 5.10. Cellular Biomedicine Group (CBMG)
  • 5.11. Conkwest
  • 5.12. CRISPR Therapeutics
  • 5.13. CytomX
  • 5.14. Editas Medicine
  • 5.15. Eureka Therapeutics
  • 5.16. Immunocore
  • 5.17. Intellia Therapeutics
  • 5.18. Intrexon, ZIOPHARM Oncology & MD Anderson
  • 5.19. Juno Therapeutics
  • 5.20. Kite Pharma
  • 5.21. Lion Biotechnologies
  • 5.22. MD Anderson Cancer Center
  • 5.23. Medigene
  • 5.24. Nextera
  • 5.25. Sorrento Therapeutics
  • 5.26. Takara Bio
  • 5.27. Transposagen Biopharmaceuticals
  • 5.28. Unum Therapeutics

6. Pharmaceutical Companies

  • 6.1. Amgen
  • 6.2. AstraZeneca
  • 6.3. Celgene
  • 6.4. Eli Lilly
  • 6.5. GlaxoSmithKline
  • 6.6. Janssen Biotech
  • 6.7. Novartis
  • 6.8. Pfizer
  • 6.9. Roche
  • 6.10. Servier

7. Stakeholder Analysis

  • 7.1. TCR Focused Companies
  • 7.2. Established CAR (& TCR) T Cell Companies
  • 7.3. Emerging and/or non-US based CAR (& TCR) T Cell Companies
  • 7.4. Technology Providers
  • 7.5.. Pharma Companies in the Field
  • 7.6. Companies with Alternative Adoptive Cell Therapies: NK Cells, TILs, DLIs & CTLs

8. Selected Technology Profiles

  • 8.1. Genome Editing Technologies
    • Allogeneic multichain chimeric Antigen Receptor (mcCAR) T-cells
    • CAR T cells and multiplex gene editing (bluebird bio)
    • Genome Editing Technology (Transposagen)
  • 8.2. Switch Technologies
    • Inducible Caspase 9 and inducible MyD88/CD40 Switch Systems
    • RheoSwitch Therapeutic System (RTS) technology
  • 8.3. Non-Viral Gene Transfer
    • Sleeping Beauty
  • 8.4. Next Generation CAR T Cell Technologies
    • Juno Therapeutics' CAR Technologies
  • 8.5. Engineered TCR T Cells
    • TCR Engineered T Cell Technology (Adaptimmune)
  • 8.6. Special Cases of CAR T Cell Construcs
    • Oncyte CAR T Cell Constructs
    • Universal Antibody-Coupled T-cell Receptor (ACTR) technology

9. Business Perspective on TCR and CAR Immunotherapeutics

  • 9.1. Deals
  • 9.2. Private Financing Rounds
  • 9.3. Public Offerings and Market Capitalization of Companies with TCR or CAR Immunotherapeutics

10. Outlook for TCR and CAR Immunotherapeutics

  • 10.1. Limitations and Hurdles with current CAR T Cell Therapies
  • 10.2. Opportunities for Novel TCR and CAR Immunotherapeutics
  • 10.3. Pricing of CAR and TCR T Cell Products
  • 10.4. Manufacturing and Commercialization

11. References

List of Tables

  • Table 1: Open Phase I/II Clinical Trials with Adaptimmune's NY-ESOc259T
  • Table 2: Planned clinical study at Dana Farber Cancer Institute with autologous T-cells expressing chimeric NKG2D receptor
  • Table 3: Pipeline of TCR T-Cell Product Candidates from Companies
  • Table 4: Pipeline of CD19 CAR T-cell product candidates from Companies
  • Table 5: Pipeline of Hematologic CAR T-cell product candidates from Companies
  • Table 6: Pipeline of Solid Tumor CAR T-cell product candidates from Companies
  • Table 7: Pipelines of NK cells, TILs, DLIs & CTLs from Companies
  • Table 8: Open Phase I/II Clinical Trials with Adaptimmune's NY-ESOc259T
  • Table 9: Bellicum's Pipeline of Cellular Product Candidates
  • Table 10: Cardio3 BioSciences' R&D Pipeline of CAR T-Cells
  • Table 11: Cellectis R&D Pipeline of UCARTs
  • Table 12: Early clinical trials at PLA General Hospital with autologous CAR T cells
  • Table 13: Conkwest's R&D pipeline of Natural Killer Cell-derived Product Candidates
  • Table 14: Goals and terms of Immunocore's partnering deals for ImmTAC technology
  • Table 15: CAR Pipeline of ZIOPARM Oncology & Intrexon & MD Anderson
  • Table 16: Profiles of Juno's lead CD19-directed T-cell product candidates
  • Table 17: Juno's Pipeline of CAR and TCR T cell product candidates
  • Table 18: Kite Pharma's Pipeline of CAR and TCR T cell product candidates
  • Table 19: Lion's Pipeline of autologous Tumor Infiltration Lymphocytes
  • Table 20: Clinical studies at MD Anderson with 2nd generation CD19 CAR T-cells co-activating via chimeric CD3z/CD28
  • Table 21: Takara Bio's Pipeline of TCR and CAR T cell product candidates
  • Table 22: Clinical study in Singapore with 3rd generation universal ACTR T-cells CD16V-BB-ζ in combination with rituximab
  • Table 23: Novartis' Pipeline of autologous CAR T-cell product candidates
  • Table 24: Major terms of collaboration between Cellectis and Pfizer
  • Table 25: Major terms of collaboration between Cellectis and Servier
  • Table 26: Competitive Profiles of the five most advanced CAR / TCR T-Cell Companies
  • Table 27: Competitive Profiles of emerging or non-US CAR / TCR T-Cell Companies
  • Table 28: Companis providing technology in the CAR T Cell Therapy field
  • Table 29: TCR and CAR Deals between Pharma and Biotech
  • Table 30: Scope of Interest of Pharma Deals for TCR & CAR Immunotherapeutics
  • Table 31: Alternative T Cell and Natural Killer Cell Immunotherapeutics
  • Table 32: TCR and CAR Deals between Pharma and Biotech
  • Table 33: Economic Terms of TCR and CAR Deals between Pharma and Biotech
  • Table 34: Biotech - Biotech Deals in the field of TCR and CAR Immunotherapeutics
  • Table 35: Private Financing Rounds of Companies with TCR or CAR Immunotherapeutics
  • Table 36: Public Offering & Market Capitalization of Companies with TCR or CAR Immunotherapeutics
  • Table 37: Opportunities for novel TCR and CAR Immunotherapeutics

List of Companies

  • Adaptimmune
  • Altor Biosciences
  • Amgen
  • Applied Immune Technologies
  • AstraZeneca
  • Autolus
  • Bellicum Pharmaceuticals
  • Bluebird bio
  • Cardio3 BioSciences
  • Celgene
  • Cellectis
  • Cellular BioMedicine Group (CBMG)
  • Conkwest
  • CRISPR Therapeutics
  • CytomX
  • Editas Medicine
  • Eli Lilly
  • Eureka Therapeutics
  • GlaxoSmithKline
  • Immunocore
  • Intellia Therapeutics
  • Intrexon
  • Janssen (J&J)
  • Juno Therapeutics
  • Kite Pharma
  • Lion Biotechnologies
  • Medigene
  • Nextera
  • Novartis
  • Pfizer
  • Roche
  • Servier
  • Sorrento Therapeutics
  • Takara Bio
  • Transposagen Biopharmaceuticals
  • Unum Therapeutics
  • ZIOPHARM Oncology
Back to Top